Vnitr Lek 2008, 54(9):842-845

Budd-Chiari syndrome - hematologists' part in the multidisciplinary approach

P. Dulíček*, J. Malý
Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Budd-Chiari syndrome presents a serious disease with a complex etiology and clinical manifestations, which is associated with high morbidity and mortality. An early diagnosis and therapy is mandatory due to the severity of disease and therapy contains the treatment of underlying disorder, anticoagulation therapy and therapy of liver impairment. We discuss hematologists' contribution to the diagnostic approach and therapy of this syndrome.

Keywords: Budd-Chiari syndrome; hematological disorders; therapy

Received: March 30, 2008; Accepted: May 20, 2008; Published: September 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P, Malý J. Budd-Chiari syndrome - hematologists' part in the multidisciplinary approach. Vnitr Lek. 2008;54(9):842-845.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol 2007; 13: 2693-2696. Go to original source... Go to PubMed...
    2. Briére JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management. Semin Tromb Hemost 2006; 32: 208-218. Go to original source... Go to PubMed...
    3. Condat B, Pessione F, Hillaire S et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-497. Go to original source... Go to PubMed...
    4. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290. Go to original source... Go to PubMed...
    5. Horton JD, San Miquel FL, Ortiz JA. Budd-Chiari syndrome: illustrated review of current management. Liver Int 2008; 1478: 455-466. Go to original source... Go to PubMed...
    6. Chung RT, Iafrate AJ, Amrein PC et al. Case records of the Massachusetts general hospital. Case 15-2006. A 46-year-old-woman with sudden onset of abdominal distention. N Engl J Med 2006; 354: 2166-2175.
    7. Kage M, Arakawa M, Kojiro M et al. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992; 102: 2081-2090. Go to original source... Go to PubMed...
    8. Kew MC, Hodkinson HJ. Membraneous obstruction of the inferior vena cava and its causal relation to hepatocellular carcinoma. Liver Int 2006; 26: 1-7. Go to original source... Go to PubMed...
    9. Janssen HL, Garcia-Pagan JC, Elias E et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364-371. Go to original source... Go to PubMed...
    10. Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg 2002; 65: 155-160. Go to PubMed...
    11. Melear JM, Goldstein RM, Levy MF et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74: 1090-1095. Go to original source... Go to PubMed...
    12. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004: 350: 578-585. Go to original source... Go to PubMed...
    13. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002; 22: 15-26. Go to original source... Go to PubMed...
    14. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející jiné myeloproliferativní choroby. Vnitř Lék 2005; 51: 741-751.
    15. Penka M, Doubek M, Schwarz J et al. Anagrelid v léčbě esenciální trombocytemie a dalších myeloproliferací s trombocytemií sledovaných v registru pacientů ČR. Vnitř Lék 2006; 52: 498-503. Go to PubMed...
    16. Robertson B, Urquhart C, Ford I et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617 F status, clonality, and antiphospholipid antibodies. J Tromb Haemost 2007; 5: 1679-1685. Go to original source... Go to PubMed...
    17. Sharma S, Texeira A, Texeira P et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40: 172-180. Go to original source... Go to PubMed...
    18. Schwarz J, Pytlík R, Doubek M et al. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 2006; 32: 231-245. Go to original source... Go to PubMed...
    19. Terabayashi H, Okuda K, Nomura F et al. Transformation of inferior vena caval thrombosis to membraneous obstruction in a patient with the lupus anticoagulant. Gastroenterology 1986; 91: 219-224. Go to original source... Go to PubMed...
    20. Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis 2002; 22: 14. Go to original source... Go to PubMed...
    21. Wang ZG, Zhang FJ, Yi MQ et al. Evolution of management for Budd-Chiari syndrome: a team's view from 2565 patients. ANZ J Surg 2005; 75: 55-63. Go to original source... Go to PubMed...
    22. Zimmerman MA, Cameron AM, Ghobrial RM et al. Budd-Chiari syndrome. Clin Liver Dis 2006; 10: 259-273. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.